C反应蛋白可预测血液透析患者动静脉内瘘通畅性丧失
该前瞻性研究纳入258例2006至2016年间在阿拉德市立医院创建动静脉内瘘(AVF)的血液透析患者,随访中位26个月,发现48.1%患者丧失AVF通畅性,C反应蛋白(CRP)水平是多因素校正后的独立预测因子(HR 1.17,95%CI 1.1-1.3,P<.0001)。
要点
- CRP水平升高是AVF通畅性丧失的独立预测因素。
- 常染色体显性多囊肾病和提前创建AVF与更好的AVF生存独立相关。
- CRP作为简单无创的慢性炎症标志物,或有助于预测AVF结局。
核心结论
- CRP水平是AVF通畅性丧失的独立预测因子。
- 常染色体显性多囊肾病和提前创建AVF与更好的AVF生存独立相关。
研究设计与样本
- 前瞻性研究,纳入2006至2016年间在阿拉德市立医院接受AVF创建的258例患者。
- 在AVF创建时收集人口学、临床和实验室特征,随访中位时间26个月。
主要发现
- 随访期间134例(51.9%)维持AVF通畅,124例(48.1%)丧失AVF通畅,平均时间23.3±28.1个月(中位10.5个月)。
- 年龄(HR 1.015,P=.035)和CRP水平(HR 1.17,P<.0001)与AVF通畅性丧失风险升高相关。
- 常染色体显性多囊肾病(HR 0.336,P=.009)、提前创建AVF(HR 0.648,P=.031)和较高甘油三酯水平(HR 0.998,P=.035)是AVF通畅的保护因素。
- 多因素校正Cox模型中,CRP水平仍为AVF通畅性丧失的独立预测因子(HR 1.17,95%CI 1.1-1.3,P<.0001)。
临床怎么用
- CRP作为简单无创的慢性炎症标志物,可用于预测AVF结局。
- 需进一步研究评估降低炎症对AVF生存的保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation is a cardiovascular risk factor in hemodialysis patients, but its influence on vascular access patency is still debatable. Our prospective study investigated this issue. METHODS: A total of 258 patients receiving an arteriovenous fistula (AVF) between 2006 and 2016 at the Municipal Hospital Arad were included. Demographic, clinical, and laboratory characteristics were collected at the time of creation of the AVF. The primary study end point was AVF patency loss, defined as an event occurring at least 2 months after AVF formation and requiring surgical revision or replacement of the fistula. The patients were followed up for a median time of 26 months. RESULTS: In our group, the mean age was 59.7 ± 13.2 years (median, 62 years), and 60.1% were male. During follow-up, 134 patients (51.9%) maintained AVF patency, whereas 124 (48.1%) lost AVF patency within a mean time of 23.3 ± 28.1 months (median, 10.5 months). We found that age (hazard ratio [HR], 1.015; P = .035) and C-reactive protein (CRP) level (HR, 1.17; P < .0001) were associated with a higher risk of loss of AVF patency. The protective factors for AVF patency were autosomal dominant polycystic kidney disease (HR, 0.336; P = .009), pre-emptive AVF (HR, 0.648; P = .031), and higher level of triglycerides (HR, 0.998; P = .035). In the multivariate adjusted Cox model, CRP level remained an independent predictor for loss of AVF patency (HR, 1.17; 95% confidence interval, 1.1-1.3; P < .0001). CONCLUSIONS: In our study, CRP level was an independent predictor of AVF patency loss, whereas better AVF survival was independently associated with autosomal dominant polycystic kidney disease and pre-emptive AVF. As a simple noninvasive marker of chronic inflammation, CRP level may be a useful tool to predict AVF outcomes. Further research is needed to assess the protective effects of inflammation reduction on AVF survival.
引用
- Stirbu O, Gadalean F, Pitea IV, et al. C-reactive protein as a prognostic risk factor for loss of arteriovenous fistula patency in hemodialyzed patients. J Vasc Surg. 2019. PMID: 30792061. doi:10.1016/j.jvs.2018.10.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。